Notably, the combined biomarkers correctly reclassified 72% of NT-proBNP false negatives in the Singapore cohort and 88% in the New Zealand cohort, most of whom had HFpEF, demonstrating the panel’s potential to significantly enhance the diagnosis and phenotyping of nonacute HF. This evidence concerns the gene NPPB and hydrops fetalis.